Is it time to abandon functional imaging in the study of neuroprotection?
Morrish
Paul
P
Hurstwood Park Neurological Centre, Princess Royal Hospital, West Sussex, United Kingdom. paul.morrish@mid-sussex.sthames.nhs.uk
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000000981:diagnostic imaging* / Q000187:drug effects; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D007211:Indoles; C046649:ropinirole; D007980:Levodopa